Legal Representation
Attorney
Timur E. Slonim, Esq.
USPTO Deadlines
Application History
19 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Aug 18, 2025 | ZZZX | Z | PREVIOUS ALLOWANCE COUNT WITHDRAWN | Loading... |
| Aug 5, 2025 | PBCR | Z | WITHDRAWN FROM PUB - OG REVIEW QUERY | Loading... |
| Jul 1, 2025 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jun 28, 2025 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Jun 28, 2025 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Jun 28, 2025 | GNEA | F | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Jun 28, 2025 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Jun 24, 2025 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jun 24, 2025 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jun 24, 2025 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jan 17, 2025 | RFNT | P | REFUSAL PROCESSED BY IB | Loading... |
| Jan 2, 2025 | RFRR | P | REFUSAL PROCESSED BY MPU | Loading... |
| Jan 2, 2025 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | Loading... |
| Dec 16, 2024 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | Loading... |
| Dec 15, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Dec 7, 2024 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Dec 6, 2024 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
| Dec 6, 2024 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Dec 5, 2024 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB | Loading... |
Detailed Classifications
Class 001
Kits comprised of biochemical reagents and assays used in scientific and laboratory research, namely, multiplex assay platform for determination of sequence integrity of DNA and RNA of target genome for therapeutic use in gene and cell therapy products; Kits comprised of biochemical reagents and assays used in scientific and laboratory research, namely, multiplex assay kits for quality control of biopharmaceutical products based on gene and cell therapy modalities; Kits comprised of biochemical reagents and assays used in scientific and laboratory research, namely, multiplex assay kits for quality control of pharmaceutical products and active ingredients
Additional Information
Design Mark
The mark consists of the word "NIBA" in black font but with the letter "A" appearing in pink, all above the word "PLEX" in a black font. To the left of the wording is a double helix with the curved bars and horizontal lines being black, and the circles at the end of the horizontal lines shifting in color from pink to purple with the bottom circle being pink and the topmost circle being purple.
Classification
International Classes
001